APOA1 and atherosclerosis: Together with advanced clinical development of reconstituted HDL per se as a drug 48, the capability of synthetic apo A‐I peptides to functionally replace human apo A‐I demonstrated in mice with CIA (this study) as well as in mice with sepsis, atherosclerosis and lung cancer 18, 19, 22 encourages further development of this HDL‐based delivery platform.